Clinical Research Directory
Browse clinical research sites, groups, and studies.
Metformin as Adjunct Therapy in Depression-Obesity Comorbidity: Clinical and Genetic Evaluation
Sponsor: Riphah International University
Summary
The patients with depression and obesity will receive add-on metformin with antidepressant therapy, which may result in greater improvement in depressive symptoms and BMI reduction compared to antidepressant monotherapy. NEGR1/RPL31P12 gene polymorphisms may influence the comparative efficacy of antidepressant monotherapy versus combination therapy (antidepressant + metformin) in Pakistani patients. Patients with certain variants may respond better or worse to antidepressants and may have different weight outcomes.
Official title: Efficacy of Metformin With Antidepressant Medication as Adjunct Therapy in Depression-Obesity Comorbidity and Association With NEGR1/RPL31P12 Variants Based on Genotyping
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2026-06-12
Completion Date
2027-06-11
Last Updated
2026-06-17
Healthy Volunteers
Yes
Interventions
Metformin
Tab 500-2000 mg/day (500 mg BD to 1000 mg BD)
Antidepressant
Sertraline 50 mg/day + Metformin 500 mg twice daily or Duloxetine 60 mg/day + Metformin 500 mg twice daily or Bupropion XL 150-300 mg/day + Metformin 500 mg twice daily
Locations (1)
Pakistan Railway Hospital
Rawalpindi, Punjab Province, Pakistan